2. Apoptosis Anti-infection Metabolic Enzyme/Protease
  3. Dengue Virus Apoptosis Bacterial Fungal Antibiotic Endogenous Metabolite Flavivirus
  4. Mycophenolic acid sodium

Mycophenolic acid sodium  (Synonyms: Mycophenolate sodium)

Cat. No.: HY-B0421A Purity: 99.98%
COA
SDS
Handling Instructions Technical Support

Mycophenolic acid sodium is a potent uncompetitive inosine monophosphate dehydrogenase (IMPDH) inhibitor with an EC50 of 0.24 µM. Mycophenolic acid sodium demonstrates antiviral effects against a wide range of RNA viruses including influenza. Mycophenolic acid sodium is an immunosuppressive agent. Antiangiogenic and antitumor effects.

For research use only. We do not sell to patients.

CAS No. : 37415-62-6

Size Price Stock Quantity
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO
ready for reconstitution
 In-stock
Solution
10 mM * 1 mL in DMSO In-stock
Solid
100 mg In-stock
500 mg In-stock
1 g In-stock
5 g In-stock
10 g   Get quote  
50 g   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 14 publication(s) in Google Scholar

Other Forms of Mycophenolic acid sodium:

Mycophenolic acid sodium Related Antibodies

Top Publications Citing Use of Products

    Mycophenolic acid sodium purchased from MedChemExpress. Usage Cited in: Nat Commun. 2024 Nov 12;15(1):9515.  [Abstract]

    Mycophenolic acid (MPA) (0, 2.5, 7.5, 15 μM) treatment caused a dose-dependent increase of IMPDH2 protein levels.

    Mycophenolic acid sodium purchased from MedChemExpress. Usage Cited in: Nat Commun. 2024 Nov 12;15(1):9515.  [Abstract]

    Mycophenolic acid (MPA) (0, 2.5, 7.5, 15 μM) treatment reduced viability at the highest concentration used (15 μM).

    Mycophenolic acid sodium purchased from MedChemExpress. Usage Cited in: Nat Commun. 2024 Nov 12;15(1):9515.  [Abstract]

    HT-IF showed that there was a significant increase in ɣH2AX signal in Mycophenolic acid (MPA) treated cells already at 7.5 μM.

    Mycophenolic acid sodium purchased from MedChemExpress. Usage Cited in: ACS Omega. 2025 Dec 8;10(50):62145-62156.  [Abstract]

    Dose response curves and % cell viability of mycophenolic acid (MPA) (10-100 μM) by MTT assay.

    Mycophenolic acid sodium purchased from MedChemExpress. Usage Cited in: J Transl Med. 2024 Feb 3;22(1):133.  [Abstract]

    The apoptotic rate was analysed after Mycophenolic acid (MPA) and/or oxaliplatin treatment compared with that of untreated cells for 24 h by flow cytosmetry analysis in HCT8/L-OHP cells.

    View All Antibiotic Isoform Specific Products:

    View All Isoforms
    Aminoglycoside Glycopeptide Lipopeptide Macrolide Oxazolidinone Quinolone Tetracycline β-lactam

    View All Endogenous Metabolite Isoform Specific Products:

    View All Isoforms
    Human Endogenous Metabolite Microbial Metabolite

    • Biological Activity

    • Purity & Documentation

    • References

    • Customer Review

    Description

    Mycophenolic acid sodium is a potent uncompetitive inosine monophosphate dehydrogenase (IMPDH) inhibitor with an EC50 of 0.24 µM. Mycophenolic acid sodium demonstrates antiviral effects against a wide range of RNA viruses including influenza. Mycophenolic acid sodium is an immunosuppressive agent. Antiangiogenic and antitumor effects[1][2].

    IC50 & Target

    Human Endogenous Metabolite

     

    In Vitro

    Mycophenolic acid sodium demonstrates antiviral effects against a wide range of RNA viruses including influenza, dengue virus, Zika virus, rotavirus, CCHFV, and hantavirus[1].
    IMPDH is the rate-limiting enzyme in the de novo synthesis of guanosine nucleotides[2].
    Mycophenolic acid (0.01-1 μM; 72 hours) sodium exhibits preferential antiproliferative activity against the endothelial cells and fibroblasts. Endothelial cells are most sensitive cells to Mycophenolic acid treatment with an IC50 <500 nM for antimitotic effects[2].
    Fibroblasts are also prone to Mycophenolic acid-induced cell cycle inhibition but exhibit a higher IC50 (<1 μM) compared with endothelial cells. The two human tumor cell lines A549 non-small cell lung cancer cells and PC3 prostate cancer cells show intermediate sensitivity with an IC50 >1 μM. U87 glioblastoma cells are resistant against Mycophenolic acid sodium treatment up to 1 μM[2].
    Mycophenolic acid (0.05-2 μM; 18 hours) sodium exhibits a dose-dependent down-regulation of HDAC2 and MYC, whereas up-regulates NDRG1[2].

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

    Mycophenolic acid sodium Related Antibodies

    Cell Proliferation Assay[2]

    Cell Line: Primary isolated human dermal microvascular endothelial cells (HDMVEC) , fibroblasts, U87 glioblastoma cells, PC3 prostate cancer cells, A549 non-small cell lung cancer cells.
    Concentration: 0.01, 0.1, 1 μM
    Incubation Time: 72 hours
    Result: Exhibited preferential antiproliferative activity against HDMVEC and fibroblasts. Whereas U87 glioblastoma cells were resistant to treatment, A549 non-small cell lung cancer and PC3 prostate cancer cells showed intermediate sensitivity.

    Western Blot Analysis[2]

    Cell Line: HDMVEC
    Concentration: 0, 0.05, 0.1, 0.5, 1, and 2 μM
    Incubation Time: 18 hours
    Result: Showed a dose-dependent regulation of HDAC2, MYC, and NDRG1.
    In Vivo

    Mycophenolic acid (120 mg/kg; oral gavage; b.i.d.) sodium exerts its antitumor effects via modulation of the tumor microenvironment, U87 tumor growth is markedly inhibited in vivo in BALB/c nude mice[2].

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

    Animal Model: Athymic 8-week-old, 20 g BALB/c nu/nu mice bearing Mycophenolic acid-resistant human U87 tumor model[2]
    Dosage: 120 mg/kg MMF (the morpholinoethyl ester prodrug of Mycophenolic acid)
    Administration: Oral gavage; b.i.d.
    Result: MMF (the morpholinoethyl ester prodrug of Mycophenolic acid) significantly inhibited tumor growth (∼70% after day 14 after tumor implantation) in MMF-treated versus control mice.
    Microvessel density (CD31 staining) and pericyte coverage determined by α-smooth muscle actin staining were markedly reduced in MMF-treated versus control tumors (44% and 78%, respectively).
    Clinical Trial
    Molecular Weight

    342.32

    Formula

    C17H19NaO6
    CAS No.
    Appearance

    Solid

    Color

    White to off-white

    SMILES

    O=C(O[Na])CC/C(C)=C/CC1=C(O)C2=C(COC2=O)C(C)=C1OC
    Structure Classification
    Initial Source
    Shipping

    Room temperature in continental US; may vary elsewhere.
    Storage

    4°C, sealed storage, away from moisture

    *In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

    Solvent & Solubility
    In Vitro: 

    DMSO : 175 mg/mL (511.22 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

    H2O : 100 mg/mL (292.12 mM; Need ultrasonic)

    Preparing
    Stock Solutions
    Concentration Solvent Mass 1 mg 5 mg 10 mg
    1 mM 2.9212 mL 14.6062 mL 29.2124 mL
    5 mM 0.5842 mL 2.9212 mL 5.8425 mL
    View the Complete Stock Solution Preparation Table

    * Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
    Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

    * Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

    • Molarity Calculator

    • Dilution Calculator

    Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

    Mass
    =
    Concentration
    ×
    Volume
    ×
    Molecular Weight *

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

    This equation is commonly abbreviated as: C1V1 = C2V2

    Concentration (start)

    C1

    ×
    Volume (start)

    V1

    =
    Concentration (final)

    C2

    ×
    Volume (final)

    V2

    In Vivo Dissolution Calculator
    Please enter the basic information of animal experiments:

    Dosage

    mg/kg

    Animal weight
    (per animal)

    g

    Dosing volume
    (per animal)

    μL

    Number of animals

    Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
    Calculation results:
    Working solution concentration: mg/mL
    This product has good water solubility, please refer to the measured solubility data in water/PBS/Saline for details.
    The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only.If necessary, please contact MedChemExpress (MCE).
    Purity & Documentation
    References

    Complete Stock Solution Preparation Table

    * Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
    Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

    Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
    H2O / DMSO 1 mM 2.9212 mL 14.6062 mL 29.2124 mL 73.0311 mL
    5 mM 0.5842 mL 2.9212 mL 5.8425 mL 14.6062 mL
    10 mM 0.2921 mL 1.4606 mL 2.9212 mL 7.3031 mL
    15 mM 0.1947 mL 0.9737 mL 1.9475 mL 4.8687 mL
    20 mM 0.1461 mL 0.7303 mL 1.4606 mL 3.6516 mL
    25 mM 0.1168 mL 0.5842 mL 1.1685 mL 2.9212 mL
    30 mM 0.0974 mL 0.4869 mL 0.9737 mL 2.4344 mL
    40 mM 0.0730 mL 0.3652 mL 0.7303 mL 1.8258 mL
    50 mM 0.0584 mL 0.2921 mL 0.5842 mL 1.4606 mL
    60 mM 0.0487 mL 0.2434 mL 0.4869 mL 1.2172 mL
    80 mM 0.0365 mL 0.1826 mL 0.3652 mL 0.9129 mL
    100 mM 0.0292 mL 0.1461 mL 0.2921 mL 0.7303 mL

    * Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

    • No file chosen (Maximum size is: 1024 Kb)
    • If you have published this work, please enter the PubMed ID.
    • Your name will appear on the site.

    Mycophenolic acid sodium Related Classifications

    Help & FAQs
    • Do most proteins show cross-species activity?

      Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

    Keywords:

    Mycophenolic acid37415-62-6MycophenolateDengue VirusApoptosisBacterialFungalAntibioticEndogenous MetaboliteFlavivirusDENVinosinemonophosphatedehydrogenaseIMPDHantiviralRNAvirusesinfluenzaimmunosuppressiveAntiangiogenicantitumorInhibitorinhibitorinhibit

    Your Recently Viewed Products:

    Inquiry Online

    Your information is safe with us. * Required Fields.

    Product Name

    		  

    Requested Quantity *

    Applicant Name *

    		 

    Salutation

    Email Address *

    		 

    Phone Number *

    Department

    		 

    Organization Name *

    City

    State

    Country or Region *

    		      

    Remarks

    Bulk Inquiry

    Inquiry Information

    Product Name:
    Mycophenolic acid sodium
    Cat. No.:
    HY-B0421A
    Quantity:
    MCE Japan Authorized Agent:

    Customer Review

    Thank You for Your Feedback!

    Request for HNMR Report

    Please fill out this form to request the QC report. We will send it to your Email address shortly.

    Your information is safe with us. * Required Fields.

    Product Name

    		  

    Lot #

    Applicant Name *

    		 

    Email Address *

    Phone Number

    		 

    Department *

    Organization Name *

    		 

    Country or Region *

    Remarks

    SAFETY DATA SHEET (SDS)

    English - EN (701 KB) Français - FR (701 KB) Deutsch - DE (701 KB) Norwegian - NO (701 KB) Español - ES (701 KB) Swedish - SV (701 KB) Italian - IT (701 KB) Korean - KR (701 KB) Portuguese - PT (701 KB)

    Request for HNMR Report

    We have received your request and will respond to you as soon as possible.